Back to search results

LINFU® Registry for Early Pancreatic Cancer Detection

This study is a registry to learn more about a new test called LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas). LINFU® aims to find early, asymptomatic (without symptoms) pancreatic cancer and precancerous lesions. The test involves a special ultrasound and analysis of pancreatic juice. You may be able to join if you are between 18 and 90 years old and have a higher risk of developing pancreatic cancer due to factors like smoking, diabetes, or family history. The study will compare how well LINFU® finds these conditions compared to standard screening methods over 5 years. The current recruitment status is unclear.

Study design
This is an observational study aiming to enroll 1000 participants. It is designed to compare a new detection method to standard screening.
What's involved
You will undergo the LINFU® procedure, which involves ultrasound and collection of pancreatic fluid. Information about your medical history and other diagnostic test results will also be collected.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes at 5 years, suggesting a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06157671

The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Enrolling by Invitation
Not specifiedAges 18–90Observational
Adenocyte, LLC
~1,000 participants
Updated 2026-08-06 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® will be compared to standard screening methods
Measured over 5 years

Conditions

Pancreatic Adenocarcinoma
Pancreatic Intraepithelial Neoplasia

Explore related trials

Pancreatic Ductal AdenocarcinomaPancreatic Intraepithelial Neoplasia

NCT06157671

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Manhattan Endoscopy Center

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gregory Haber, MD FRCP · PRINCIPAL_INVESTIGATOR · Manhattan Endoscopy Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Both males and females will be enrolled and must be at least 18 years of age under age of 90
Patients who, in the opinion of the Investigator, are at elevated risk of developing a pancreatic malignancy because they have known risk factors for PDAC.
High risk asymptomatic patients being screened for PDAC.
All patients must undergo contemporaneous imaging (within 90 days of LINFU®) with one or more of the following: EUS± FNA, MRI/MRCP, ERCP, CT or CEUS.
Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.

Exclusion

Patient under the age of 18 and over the age 90
Contraindications to LINFU®/EUS/ERCP as determined by study investigators including: patient with uncorrectable coagulopathy; patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist; unstable medically (cardiopulmonary, neurologic, or cardiovascular status)
Patients with clinical signs or symptoms of PDAC
Patients undergoing EUS or ERCP for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium
Patients with documented intraductal papillary mucinous neoplasm of the pancreas (IPMN)
Pregnant females will be excluded
Patient that is unable to provide informed consent
Patient with known allergy to the microbubble contrast agent or secretin

What this trial measures

  • The number of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® will be compared to standard screening methods5 years

    The total number of asymptomatic pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® by analysis of pancreatic fluid will be compared to the number of these lesions identified with current screening tests, including EUS- FNA, MRI/MRCP, ERCP, CT and CEUS.